Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529001 | PMC |
| http://dx.doi.org/10.1016/S2468-1253(23)00188-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic Accuracy of a Blood-Based Biomarker Panel for Colorectal Cancer Detection: A Pilot Study.
Cancers (Basel)
December 2024
Division of Clinical and Translational Cancer Research, University of Puerto Rico Comprehensive Cancer Center, San Juan 00921, Puerto Rico.
Colorectal cancer (CRC) is a leading cause of death worldwide. Despite its preventability through screening, compliance still needs to improve due to the invasiveness of current tools. There is a growing demand for validated molecular biomarker panels for minimally invasive blood-based CRC screening.
View Article and Find Full Text PDFPlasma-based transcriptomic non-coding signature for predicting relapse in pediatric acute lymphoblastic leukemia.
Heliyon
December 2024
Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.
Pediatric Acute Lymphoblastic Leukemia (ALL) is the most common malignant tumor of the hematological system in children, and its relapse after treatment has consistently been a significant factor hindering prognosis. This study aimed to develop a blood-based non-invasive method for predicting relapse in children with ALL. Two cohorts of pediatric ALL patients were analyzed.
View Article and Find Full Text PDFEthical Considerations and Implications of Multi-Cancer Early Detection Screening: Reliability, Access and Cost to Test and Treat.
Camb Q Healthc Ethics
January 2025
Precision Health Program, Michigan State University, East Lansing, MI, USA.
This essay focuses on the ethical considerations and implications of providing a universal multi-cancer screening test as the best approach to reduce societal cancer burden in a society with limited funds, resources, and infrastructure. With 1.9 million cancer diagnoses each year in the United States, with 86% of all cancers diagnosed in individuals over the age of 50, and with screening tools approved for only four cancer types (breast, cervical, colorectal, and lung cancer), it seems that a multi-cancer screening test to detect most cancer early that is easy to administer, and is accurate and cost-effective, would be worth considering.
View Article and Find Full Text PDFExploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer.
Clin Colorectal Cancer
December 2024
Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Faculty of Technology, Natural Sciences and Maritime Sciences, University of South-Eastern Norway, Bø in Telemark, Norway.
Article Synopsis
- Early identification of patients with metastatic colorectal cancer (mCRC) who may not benefit from first-line chemotherapy could guide the timely use of second-line treatments, potentially improving outcomes.
- The study analyzed the relationship between changes in carcinoembryonic antigen (CEA), circulating cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA) during chemotherapy, finding that early ctDNA changes are more predictive of treatment response and survival outcomes than CEA.
- Results indicated that lack of a strong molecular response in ctDNA by the first evaluation was linked to shorter progression-free survival (PFS) and overall survival (OS), highlighting ctDNA's potential as a valuable biomarker in monitoring mCRC treatment.
Adherence to recommended blood-based screening tests for cancer and chronic diseases: A systematic literature review.
Prev Med
December 2024
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Introduction: Blood-based tests represent a compelling option for early detection and management of cancers and other chronic diseases. While they may increase patient engagement, assumptions about greater adherence in clinical practice need further evaluation. This systematic review aimed to evaluate real-world adherence to established blood-based tests for commonly recommended screening indications to inform expectations for average-risk colorectal cancer (CRC) screening.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!